Lume‑LifeBio: A Deterministic Governance Substrate for Biological, Pharmaceutical, and Biomanufacturing Systems

Biological and pharmaceutical systems operate under extreme safety, regulatory, and precision constraints — involving complex multi‑stage processes from genomic analysis to biologics manufacturing, from sterile processing to cold‑chain distribution. Yet today, bio‑pharmaceutical governance is nondeterministic, fragmented, and disconnected from the physical substrates that determine product safety, sterility assurance, and contamination response. Existing systems — GMP protocols, GLP frameworks, FDA/EMA guidelines, and batch management platforms — operate in silos, lack cross‑vertical awareness, and provide no replay‑identical audit capability.

This paper introduces Lume‑LifeBio, the first deterministic governance substrate for biological, pharmaceutical, and biomanufacturing systems. Built on the Lume‑V governance layer and the Lume‑Ops universal operational substrate, Lume‑LifeBio integrates genomic pipeline governance, bioprocessing and bioreactor control, sterile manufacturing safety, cold‑chain integrity for biologics, cleanroom environmental control, and recall propagation into a single replay‑identical state machine. It enforces biological invariants, bioprocess envelopes, deterministic multi‑agent arbitration, override logic with deterministic rollback, and certificate‑based auditability across the full biomanufacturing pipeline — from genomic input to bioprocessing to manufacturing to cold‑chain to clinical delivery.